Expert Reimbursement Support On Site |
INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
INOMAX Important Safety Information (ISI)
INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
Reimbursement Support
An Ikaria® national account manager will help address your reimbursement requests through the following services:
- Managed Care Update to highlight local, regional, and national reimbursement trends
- Situational Assessment working with your finance and clinical teams to help identify your facility’s current reimbursement strategies regarding INOMAX
- Strategic Assessment to develop recommendations and best practices for your revenue cycle team to help optimize appropriate INOMAX reimbursement
- Long-term Support facilitating periodic reviews to foster continuous improvement to your processes
Other Resources
Reimbursement questions?
Call today to set up a meeting: 1-877-566-9466 or Contact Us.